Toxys is an innovative Dutch biotech company that develops unique animal-free laboratory tests for the safety assessment of novel medicines, chemicals, cosmetics and food. Today, Toxys announces a \u20ac2 million funding round from KIKK Capital, InnovationQuarter, Zeeland Investment fund, Toxys management and Rabobank.<\/p>\n\n\n\n
This investment is being made to advance Toxys\u2019 ambition to become the global leading supplier of expert mechanistic in vitro<\/em> chemical safety testing services. These services provide animal-free safety testing of novel medicines, chemicals and consumer products. The patented ToxTracker\u00ae assay can identify toxic and carcinogenic properties of novel pharmaceuticals, agrochemicals and fine chemicals already at an early stage of drug\/product development. ToxTracker can prevent the unnecessary rejections of highly valuable drug candidates and products, reduce drug\/product development time lines and can prevent unnecessary animal testing. ToxTracker has the unique ability to identify the mode-of-action of toxic compounds which significantly improves the ability to predict and reduce risks for human health. ToxTracker is currently under review by the international authorities for official acceptance and inclusion of the test systems within the standard regulatory safety test strategy. Furthermore, with its soon-to-be launched novel ReproTracker\u00ae test, Toxys aims to fill a large unmet need for an in vitro<\/em> embryo toxicity test.<\/p>\n\n\n\n
![\"\"\/](\"https:\/\/mcusercontent.com\/bcbcc07168d0c5b9525b6b71e\/images\/b772b2a1-8d9c-4b80-80e6-4ae30bf4a93c.jpeg\")
<\/figure><\/div>\n\n\n\n